Toxicological considerations for intravitreal drugs

Expert Opinion on Drug Metabolism and Toxicology

Volumn 7, Issue 8, 2011, Pages 1021-1034

  Penha, Fernando M ^a   Rodrigues, Eduardo B ^a   Furlani, Bruno A ^a   Dib, Eduardo ^a   Melo, Gustavo B ^a   Farah, Michel E ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

bevacizumab; corticosteroids; monoclonal antibodies; ranibizumab; retina; retinal pharmacotherapy; triamcinolone; tumor necrosis factor; vascular endothelial growth factor; VEGF trap

Indexed keywords

ADALIMUMAB; AFLIBERCEPT; AMIKACIN; AMINOGLYCOSIDE; AMPHOTERICIN B; BEVACIZUMAB; CEFAZOLIN; CEFTAZIDIME; CIPROFLOXACIN; CLINDAMYCIN; DEXAMETHASONE; ETANERCEPT; FLUCONAZOLE; FLUOCINOLONE ACETONIDE; GATIFLOXACIN; GENTAMICIN; INFLIXIMAB; KH 902; MOXIFLOXACIN; NETILMICIN; PAZOPANIB; RANIBIZUMAB; SUNITINIB; TOBRAMYCIN; TRIAMCINOLONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR; VERTEPORFIN;

ANGIOGENIC DISEASE; ANTIBIOTIC SENSITIVITY; APOPTOSIS; ASPERGILLUS; CANDIDA ENDOPHTHALMITIS; CATARACT; CLINICAL ASSESSMENT; COLORECTAL CANCER; CONJUNCTIVAL HEMORRHAGE; DIABETIC MACULAR EDEMA; DRUG CHOICE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ELECTRORETINOGRAPHY; ENDOPHTHALMITIS; EVOKED VISUAL RESPONSE; EXUDATIVE MACULAR DEGENERATION; EYE INFLAMMATION; EYE PAIN; EYE TOXICITY; FOLLOW UP; FUNGAL ENDOPHTHALMITIS; GASTROINTESTINAL TUMOR; GLAUCOMA; HEART INFARCTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTRAOCULAR HYPERTENSION; KIDNEY CARCINOMA; METASTASIS; METASTATIC COLORECTAL CANCER; MULTICENTER STUDY (TOPIC); NEPHROTOXICITY; OPTICAL COHERENCE TOMOGRAPHY; OTOTOXICITY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PIGMENT EPITHELIUM; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA CELL; RETINA DISEASE; RETINA INJURY; RETINA MACULA AGE RELATED DEGENERATION; RETINA TEAR; RETINA VEIN OCCLUSION; REVIEW; SIDE EFFECT; STAPHYLOCOCCUS AUREUS; STROKE; SUBRETINAL NEOVASCULARIZATION; SYSTEMIC DISEASE; TRANSMISSION ELECTRON MICROSCOPY; TREATMENT OUTCOME; UVEITIS; VEIN OCCLUSION; VISUAL ACUITY; VITRECTOMY; VITREOUS FLOATERS; VITREOUS HEMORRHAGE; VITRITIS;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; CLINICAL TRIALS AS TOPIC; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MACULAR EDEMA; TRIAMCINOLONE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79960553434     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2011.585970     Document Type: Review

References (101)

1. Brechner RJ, Rosenfeld PJ, Babish JD, Caplan S, et al. Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 medicare fee-for-service part B claims file. Am J Ophthalmol 2011;151(5):887-95
2. Ohm J. Uber die behandlung der netzhautablosung durch operative entleerung der subretinalen flussigkeit und einspritzung von luft in den glaskoper. Graefes Arch Clin Exp Ophthalmol 1911;79:442-50
3. Friedman AH, Orellana J, Freeman WR, et al. Cytomegalovirus retinitis: a manifestation of the acquired immune deficiency syndrome (AIDS). Br J Ophthalmol 1983;67:372-80 (Pubitemid 13106213)
4. Bhatnagar P, Spaide RF, Takahashi BS, et al. Ranibizumab for treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2007;7:846-50 (Pubitemid 47479378)
5. Blick SK, Keating GM, Wagstaff AJ. Ranibizumab. Drugs 2007;67:1199-206; discussion 1207-1209 (Pubitemid 46871027)
6. Novack GD. Pharmacotherapy for the treatment of choroidal neovascularization due to age-related macular degeneration. Annu Rev Pharmacol Toxicol 2008;48:61-78 (Pubitemid 351738149)
7. Vavvas D, D?Amico DJ. Pegaptanib (Macugen): treating neovascular age-related macular degeneration and current role in clinical practice. Ophthalmol Clin North Am 2006;19:353-60 (Pubitemid 44403945)
8. Maia M, Farah ME, Belfort RN, et al. Effects of intravitreal triamcinolone acetonide injection with and without preservative. Br J Ophthalmol 2007;91:1122-4 (Pubitemid 47344879)
9. Maia M, Penha FM, Farah ME, et al. Subretinal injection of preservative-free triamcinolone acetonide and supernatant vehicle in rabbits: an electron microscopy study. Graefes Arch Clin Exp Ophthalmol 2008;246:379-88
10. Azab M, Boyer DS, Bressler NM, et al. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol 2005;123:448-57 (Pubitemid 40489914)
11. Aggio FB, Farah ME, Silva WC, Melo GB. Intravitreal bevacizumab for exudative age-related macular degeneration after multiple treatments. Graefes Arch Clin Exp Ophthalmol 2007;245:215-20 (Pubitemid 46291451)
12. Jonas JB, Libondi T, Ihloff AK, et al. Visual acuity change after intravitreal bevacizumab for exudative age-related macular degeneration in relation to subfoveal membrane type. Acta Ophthalmol Scand 2007;85:563-5 (Pubitemid 47163119)
13. Arevalo JF, Fromow-Guerra J, Sanchez JG, et al. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up. Retina 2008;28:1387-94
14. Avery RL. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 2006;26:352-4 (Pubitemid 44318195)
15. Bashshur ZF, Haddad ZA, Schakal AR, et al. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: the second year of a prospective study. Am J Ophthalmol 2009;148:59-65 e1
16. Bonini-Filho M, Costa RA, Calucci D, et al. Intravitreal bevacizumab for diabetic macular edema associated with severe capillary loss: one-year results of a pilot study. Am J Ophthalmol 2009;147:1022-30, 30 e1-5
17. Arevalo JF, Garcia-Amaris RA, Roca JA, et al. Primary intravitreal bevacizumab for the management of pseudophakic cystoid macular edema: pilot study of the Pan-American Collaborative Retina Study Group. J Cataract Refract Surg 2007;33:2098-105 (Pubitemid 350167520)
18. Donati MC, Virgili G, Bini A, et al. Intravitreal bevacizumab (Avastin) for choroidal neovascularization in angioid streaks: a case series. Ophthalmologica 2009;223:24-7
19. Iriyama A, Chen YN, Tamaki Y, Yanagi Y. Effect of anti-VEGF antibody on retinal ganglion cells in rats. Br J Ophthalmol 2007;91:1230-3 (Pubitemid 47344905)
20. Luke M, Warga M, Ziemssen F, et al. Effects of bevacizumab on retinal function in isolated vertebrate retina. Br J Ophthalmol 2006;90:1178-82 (Pubitemid 44351153)
21. Luthra S, Narayanan R, Marques LE, et al. Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells. Retina 2006;26:512-18 (Pubitemid 44620391)
22. Bakri SJ, Cameron JD, McCannel CA, et al. Absence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit model. Am J Ophthalmol 2006;142:162-4 (Pubitemid 43946808)
23. Heiduschka P, Fietz H, Hofmeister S, et al. Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 2007;48:2814-23 (Pubitemid 351261238)
24. Inan UU, Avci B, Kusbeci T, et al. Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes. Invest Ophthalmol Vis Sci 2007;48:1773-81 (Pubitemid 351261365)
25. Manzano RP, Peyman GA, Khan P, Kivilcim M. Testing intravitreal toxicity of bevacizumab (Avastin). Retina 2006;26:257-61 (Pubitemid 44318176)
26. Peters S, Heiduschka P, Julien S, et al. Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol 2007;143:995-1002
27. Chan CK, Lin SG. Retinal pigment epithelial tear after ranibizumab therapy for subfoveal fibrovascular pigment epithelial detachment. Eur J Ophthalmol 2007;17:674-6 (Pubitemid 351175350)
28. Rodrigues EB, Shiroma H, Meyer CH, et al. Metrorrhagia after intravitreal injection of bevacizumab. Acta Ophthalmol Scand 2007;85:915-16
29. Adelman RA, Zheng Q, Mayer HR. Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections. J Ocul Pharmacol Ther 2010;26:105-10
30. Kahook MY, Kimura AE, Wong LJ, et al. Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections. Ophthalmic Surg Lasers Imaging 2009;40:293-5
31. Semoun O, Blumen-Ohana E, de Preobrajensky N, Nordmann JP. Acute angle-closure glaucoma complicating an intravitreal injection of bevacizumab. J Fr Ophtalmol 2009;32:58 e1-4
32. Shima C, Sakaguchi H, Gomi F, et al. Complications in patients after intravitreal injection of bevacizumab. Acta Ophthalmol 2008;86:372-6
33. Shouten JS, La Heij EC, Webers CA, et al. A systematic review on the effect of bevacizumab in exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2009;247:1-11
34. Martin DF, Maguire MG, Ying GS, et al. CATT Rsearch group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364(20):1897-908
35. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006;90:1344-9 (Pubitemid 44702055)
36. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-44 (Pubitemid 44511558)
37. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 2009;116:57-65 e5
38. Mitchell P, Korobelnik JF, Lanzetta P, et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol 2010;94:2-13
39. Rosenfeld PJ. Intravitreal avastin: the low cost alternative to lucentis? Am J Ophthalmol 2006;142:141-3 (Pubitemid 43946805)
40. Rosenfeld PJ. New treatments for age-related macular degeneration. Lancet 2007;370:1479; author reply 1480 (Pubitemid 47625550)
41. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002;99:11393-8 (Pubitemid 34920936)
42. Chappelow AV, Kaiser PK. Neovascular age-related macular degeneration: potential therapies. Drugs 2008;68:1029-36 (Pubitemid 351693673)
43. Rudge JS, Thurston G, Davis S, et al. VEGF trap as a novel antiangiogenic treatment currently in clinical trials for cancer and eye diseases, and VelociGenebased discovery of the next generation of angiogenesis targets. Cold Spring Harb Symp Quant Biol 2005;70:411-18 (Pubitemid 44124896)
44. Nguyen QD, Shah SM, Browning DJ, et al. A Phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration. Ophthalmology 2009;116:2141-8 e1
45. Regeneron Pharmaceuticals. Vascular Endothelial Growth Factor (VEGF)Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD). ClinicalTrials.gov NCT00509795. Available from: http://clinicaltrials.gov/ct2/show/NCT00509795? term=NCT00509795&rank=1
46. Zhang M, Yu D, Yang C, et al. The pharmacology study of a new recombinant human VEGF receptor-fc fusion protein on experimental choroidal neovascularization. Pharm Res 2009;26:204-10
47. Suto K, Yamazaki Y, Morita T, Mizuno H. Crystal structures of novel vascular endothelial growth factors (VEGF) from snake venoms: insight into selective VEGF binding to kinase insert domain-containing receptor but not to fms-like tyrosine kinase-1. J Biol Chem 2005;280:2126-31
48. Dick AD, Forrester JV, Liversidge J, Cope AP. The role of tumour necrosis factor (TNF-alpha) in experimental autoimmune uveoretinitis (EAU). Prog Retin Eye Res 2004;23:617-37 (Pubitemid 39243969)
49. Imrie FR, Dick AD. Biologics in the treatment of uveitis. Curr Opin Ophthalmol 2007;18:481-6 (Pubitemid 351339402)
50. Giansanti F, Ramazzotti M, Vannozzi L, et al. A pilot study on ocular safety of intravitreal infliximab in a rabbit model. Invest Ophthalmol Vis Sci 2008;49:1151-6
51. Fauser S, Kalbacher H, Alteheld N, et al. Pharmacokinetics and safety of intravitreally delivered etanercept. Graefes Arch Clin Exp Ophthalmol 2004;242:582-6 (Pubitemid 39157687)
52. Kivilcim M, Peyman GA, Kazi AA, et al. Intravitreal toxicity of high-dose etanercept. J Ocul Pharmacol Ther 2007;23:57-62 (Pubitemid 46449302)
53. Manzano RP, Peyman GA, Carvounis PE, et al. Ocular toxicity of intravitreous adalimumab (Humira) in the rabbit. Graefes Arch Clin Exp Ophthalmol 2008;246:907-11
54. Galor A, Perez VL, Hammel JP, Lowder CY. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology 2006;113:2317-23 (Pubitemid 44838928)
55. Tynjala P, Lindahl P, Honkanen V, et al. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis 2007;66:548-50 (Pubitemid 46580481)
56. Wu L, Hernandez-Bogantes E, Roca JA, et al. Intravitreal tumor necrosis factor inhibitors in the treatment of refractory diabetic macular edema: a pilot study from the Pan-American Collaborative Retina Study Group. Retina 2011;31:298-303
57. Giganti M, Beer PM, Lemanski N, et al. Adverse events after intravitreal infliximab (Remicade). Retina 2010;30:71-80
58. Kumar R, Knick VB, Rudolph SK, et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 2007;6:2012-21 (Pubitemid 47052491)
59. Takahashi K, Saishin Y, King AG, et al. Suppression and regression of choroidal neovascularization by the multitargeted kinase inhibitor pazopanib. Arch Ophthalmol 2009;127:494-9
60. Yafai Y, Niemeyer M, Yasukawa T, et al. Inhibition of experimental choroidal neovascularization by the VEGF receptor inhibitor pazopanib (GW786034B). Invest Ophthalmol Vis Sci 2008;49:E-abstract 534
61. McLaughlin MM, Bayliffe A, Hunt T, et al. A multi-targeted receptor tyrosine kinase inhibitor for the treatment of neovascular AMD: results of a healthy volunteer safety and tolerability study of pazopanib eye drops. Invest Ophthalmol Vis Sci 2009;50:E-abstract 5008
62. GlaxoSmithKline. An Extension to Study MD7108240. ClinicalTrials.gov NCT00733304. Available from: http://clinicaltrials.gov/ct2/show/NCT00733304? term= NCT00733304&rank=1
63. Dib E, Maia M, Costa EPF, et al. In vitro and in vivo toxicity of sutinib maleate. Invest Ophthalmol Vis Sci 2010;51:E-abstract 2817
64. Hancock HA, Guidry C, Read RW, et al. Acute aminoglycoside retinal toxicity in vivo and in vitro. Invest Ophthalmol Vis Sci 2005;46:4804-8 (Pubitemid 44264587)
65. D?Amico DJ, Caspers-Velu L, Libert J, et al. Comparative toxicity of intravitreal aminoglycoside antibiotics. Am J Ophthalmol 1985;100:264-75 (Pubitemid 15240587)
66. Mochizuki K, Torisaki M, Yamashita Y, et al. Effects of aminoglycosides on the rabbit in-vivo ERG. Nippon Ganka Gakkai Zasshi 1989;93:80-5 (Pubitemid 19072512)
67. Oum BS, D?Amico DJ, Kwak HW, Wong KW. Intravitreal antibiotic therapy with vancomycin and aminoglycoside: examination of the retinal toxicity of repetitive injections after vitreous and lens surgery. Graefes Arch Clin Exp Ophthalmol 1992;230:56-61
68. Almeida LN, Canedo MG, Almeida RN, et al. Macular infarction after intravitreal injection of amikacin: case report. Arq Bras Oftalmol 2005;68:837-40 (Pubitemid 44110334)
69. Campochiaro PA, Green WR. Toxicity of intravitreous ceftazidime in primate retina. Arch Ophthalmol 1992;110:1625-9
70. Sonmez M, Unal MH, Yildiz TF, Gulecek O. Retinal toxicity of intraocular vancomycin and ceftazidime in vitrectomized rabbit eyes. Drug Chem Toxicol 2006;29:125-34 (Pubitemid 43286717)
71. Hegazy HM, Kivilcim M, Peyman GA, et al. Evaluation of toxicity of intravitreal ceftazidime, vancomycin, and ganciclovir in a silicone oil-filled eye. Retina 1999;19:553-7 (Pubitemid 30387492)
72. Borhani H, Peyman GA, Wafapoor H. Use of vancomycin in vitrectomy infusion solution and evaluation of retinal toxicity. Int Ophthalmol 1993;17:85-8 (Pubitemid 23263103)
73. Zimmer-Galler IE, Santos A, Haller JA, Campochiaro PA. Management of endophthalmitis in a silicone oil-filled eye. Retina 1997;17:507-9 (Pubitemid 28032432)
74. Fiscella RG. Physical incompatibility of vancomycin and ceftazidime for intravitreal injection. Arch Ophthalmol 1993;111:730 (Pubitemid 23170575)
75. Wiechens B, Grammer JB, Johannsen U, et al. Experimental intravitreal application of ciprofloxacin in rabbits. Ophthalmologica 1999;213:120-8 (Pubitemid 29049398)
76. Kernt M, Neubauer AS, De Kaspar HM, Kampik A. Intravitreal voriconazole: in vitro safety-profile for fungal endophthalmitis. Retina 2009;29:362-70
77. Aydin E, Kazi AA, Peyman GA, Esfahani MR. Intravitreal toxicity of moxifloxacin. Retina 2006;26:187-90 (Pubitemid 44400715)
78. Thompson AM. Ocular toxicity of fluoroquinolones. Clin Experiment Ophthalmol 2007;35:566-77 (Pubitemid 47337975)
79. Khan FA, Slain D, Khakoo RA. Candida endophthalmitis: focus on current and future antifungal treatment options. Pharmacotherapy 2007;27:1711-21 (Pubitemid 350234318)
80. Mochizuki K, Yamashita Y, Torisaki T, et al. Intraocular penetration and effect on the retina of fluconazole. Lens Eye Toxic Res 1992;9:537-46 (Pubitemid 23111724)
81. Cheng CK, Yang CH, Hsueh PR, et al. Vitrectomy with fluconazole infusion: retinal toxicity, pharmacokinetics, and efficacy in the treatment of experimental candidal endophthalmitis. J Ocul Pharmacol Ther 2004;20:430-8
82. Hariprasad SM, Mieler WF, Lin TK, et al. Voriconazole in the treatment of fungal eye infections: a review of current literature. Br J Ophthalmol 2008;92:871-8 (Pubitemid 351969658)
83. Gao H, Pennesi M, Shah K, et al. Safety of intravitreal voriconazole: electroretinographic and histopathologic studies. Trans Am Ophthalmol Soc 2003;101:183-9; discussion 189 (Pubitemid 38209327)
84. Sen P, Gopal L, Sen PR. Intravitreal voriconazole for drug-resistant fungal endophthalmitis: case series. Retina 2006;26:935-9 (Pubitemid 44547449)
85. Jaffe GJ, Yang CH, Guo H, et al. Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device. Invest Ophthalmol Vis Sci 2000;41:3569-75
86. Holekamp NM, Thomas MA, Pearson A. The safety profile of long-term, high-dose intraocular corticosteroid delivery. Am J Ophthalmol 2005;139:421-8 (Pubitemid 40379067)
87. Kwak HW, D?Amico DJ. Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection. Arch Ophthalmol 1992;110:259-66
88. Yu SY, Damico FM, Viola F, et al. Retinal toxicity of intravitreal triamcinolone acetonide: a morphological study. Retina 2006;26:531-6 (Pubitemid 44620394)
89. Ishibashi T, Miki K, Sorgente N, et al. Effects of intravitreal administration of steroids on experimental subretinal neovascularization in the subhuman primate. Arch Ophthalmol 1985;103:708-11 (Pubitemid 15052411)
90. Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, et al. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology 2007;114:743-50 (Pubitemid 46483714)
91. Dyer D, Callanan D, Bochow T, et al. Clinical evaluation of the safety and efficacy of preservative-free triamcinolone (triesence [triamcinolone acetonide injectable suspension] 40 mg/ml) for visualization during pars plana vitrectomy. Retina 2009;29:38-45
92. Moshfeghi AA, Nugent AK, Nomoto H, et al. Triamcinolone acetonide preparations: impact of crystal size on in vitro behavior. Retina 2009;29:689-98
93. Kai W, Yanrong J, Xiaoxin L. Vehicle of triamcinolone acetonide is associated with retinal toxicity and transient increase of lens density. Graefes Arch Clin Exp Ophthalmol 2006;244:1152-9 (Pubitemid 44269594)
94. Lang Y, Leibu R, Shoham N, et al. Evaluation of intravitreal kenalog toxicity in humans. Ophthalmology 2007;114:724-31 (Pubitemid 46483697)
95. Abramson DH, Dunkel IJ, Brodie SE, et al. A Phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results. Ophthalmology 2008;115(8):1398-404, 1404 e1
96. Macky TA, Helmy D, El Shazly N. Retinal toxicity of triamcinolone?s vehicle (benzyl alcohol): an electrophysiologic and electron microscopic study. Graefes Arch Clin Exp Ophthalmol 2007;245:817-24 (Pubitemid 46805612)
97. Rodriguez-Coleman H, Yuan P, Kim H, et al. Intravitreal injection of triamcinolone for diffuse macular edema. Arch Ophthalmol 2004;122:1085-6; author reply 1086-1088
98. Macky TA, Oelkers C, Rix U, et al. Synthesis, pharmacokinetics, efficacy, and rat retinal toxicity of a novel mitomycin C-triamcinolone acetonide conjugate. J Med Chem 2002;45:1122-7 (Pubitemid 34173922)
99. Lang Y, Zemel E, Miller B, Perlman I. Retinal toxicity of intravitreal kenalog in albino rabbits. Retina 2007;27:778-88 (Pubitemid 47051776)
100. Li Q, Wang J, Yang L, et al. A moephologic study of retinal toxicity induced by triamcinolone acetonide vehicles in rabbit eyes. Retina 2008;28:504-10 (Pubitemid 351354955)
101. Loewenstein A, Zemel E, Lazar M, Perlman I. The effects of Depo-Medrol preservative on the rabbit visual system. Invest Ophthalmol Vis Sci 1991;32:3053-60